VCAM1 and lung cancer: Both of these qualities may make VCAM-1-D6 huMab an attractive candidate therapeutic for potential use in combination with existing chemotherapies to suppress the invasion of VCAM-1-expressing lung cancer cells in human lung cancer patients.